Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

990

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Placebo for pembrolizumab
DRUG: Docetaxel
DRUG: Cisplatin
RADIATION: External Beam Radiotherapy (EBRT)
DRUG: Cisplatin (as radiosensitizer)
RADIATION: Brachytherapy

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]
[object Object]